Artal Group S.A. Lexicon Pharmaceuticals, Inc. Transaction History
Artal Group S.A.
- $214 Million
- Q3 2024
A detailed history of Artal Group S.A. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 136,180,481 shares of LXRX stock, worth $113 Million. This represents 100.0% of its overall portfolio holdings.
Number of Shares
136,180,481
Previous 175,099,384
22.23%
Holding current value
$113 Million
Previous $294 Million
27.32%
% of portfolio
100.0%
Previous 18.64%
Shares
8 transactions
Others Institutions Holding LXRX
# of Institutions
141Shares Held
238MCall Options Held
459KPut Options Held
133K-
Siren, L.L.C. New York, NY38.9MShares$32.3 Million3.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA11MShares$9.15 Million0.41% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$8.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.09MShares$6.72 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.52MShares$2.92 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $157M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...